FREDERICK, Md., May 14, 2014 /PRNewswire/ -- BioElectronics
Corporation (OTC Pink: BIEL), the maker of advanced drug-free
consumer medical devices, today announced more detail on the
interim results of a randomized, double blind, placebo controlled
trial on osteoarthritis of the knee (knee pain) using ActiPatch®
Therapy. The interim results are now published online at the
EULAR (European League against Arthritis) conference website at
https://b-com.mci-group.com/AbstractList/EULAR2014.aspx and search
for abstract #: AB0777.
"Arthritis is the major cause of disability in the US affecting
52.5 million adults. Osteoarthritis of the knee is the most common
musculoskeletal pain and disability condition. Therefore we are
extremely pleased by the results of Dr. Gianluca Bagnato's clinical study," commented
Ian Rawe, Ph.D. Director of
Research, BioElectronics. Dr. Rawe noted that the study
looked at three important measures associated with Osteoarthritis,
these being pain, ease of movement and overall patient quality of
life. "Importantly the study results show significant improvement
in all three measures for the group wearing the active ActiPatch
device relative to the group wearing the non-active device. We take
these results as strong support for our contention that our
affordable innovative drug-free technology can greatly reduce
disabilities, physician office visits, and the reliance on drugs
for chronic pain."
ActiPatch® Musculoskeletal Pain Therapy devices are readily
available, over-the-counter outside of the US, for approximately
$30.00, or $0.04 per hour of therapy.
The specific four weeks of ActiPatch® Therapy showed the
following:
- Patients treated with ActiPatch® Therapy showed a statistically
significant improvement in visual analogue pain scores (VAS)
(p<0.005) and WOMAC* pain scores (p<0.001) at 4 weeks
compared to baseline.
- Patients treated with ActiPatch® Therapy assessed for function
and disability showed statistically significant improvement for
WOMAC* function (p<0.002) and WOMAC* stiffness (p<0.02) at 4
weeks compared to baseline.
- Patients treated with ActiPatch® Therapy also demonstrated
statistically significant (p<0.04) improved physical and mental
health as assessed by the SF-36 (36-item Medical Outcomes Study
Short-Form 36 version 2) at 4 weeks compared to baseline.
- No statistically significant results were recorded in the
placebo group.
[*WOMAC - Western Ontario and
McMaster Universities Osteoarthritis Index]
Other Clinical Research
BioElectronics is conducting a series of clinical research
studies using its medical devices. Details can be found at
http://www.bielcorp.com/clinical-evidence/ along with details of
previously completed and published clinical trials.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the
maker of an industry leading family of disposable, drug-free,
anti-inflammatory devices: ActiPatch® Therapy,
over-the-counter treatment for back pain and other musculoskeletal
complaints; RecoveryRx® Devices for chronic and
post-operative wound care; Allay® Menstrual Pain
Therapy; and HealFast® Therapy for dogs, cats and
horses. For more information, please visit
www.bielcorp.com.
Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com
SOURCE BioElectronics Corporation